Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | DAGLA | Q9Y4D2 | 3/20 | 0.41 |
| ▸ | ABHD11 | Q8NFV4 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3607904 | 1.00 | L3MBTL1 (0.48) | L3MBTL1POLBNPC1RAB9AKMT2A | |
| SCHEMBL3348343 | 1.00 | L3MBTL1 (0.48) | L3MBTL1POLBNPC1RAB9AKMT2A | |
| SCHEMBL1198628 | 0.94 | NPC1 (0.52) | L3MBTL1NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL22287170 | 0.87 | — | — | |
| SCHEMBL15826612 | 0.86 | L3MBTL1 (0.57) | L3MBTL1POLBNPC1RAB9AKMT2A | |
| SCHEMBL28771469 | 0.84 | POLB (0.46) | L3MBTL1POLBNPC1RAB9AKMT2A | |
| SCHEMBL12518184 | 0.84 | POLB (0.46) | L3MBTL1POLBNPC1RAB9AKMT2A | |
| SCHEMBL4863166 | 0.83 | POLB (0.38) | L3MBTL1POLBNPC1RAB9AKMT2A | |
| SCHEMBL10118444 | 0.83 | POLB (0.48) | L3MBTL1POLBNPC1RAB9AKMT2A | |
| SCHEMBL3489993 | 0.83 | POLB (0.48) | L3MBTL1POLBNPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059937-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION | 2011-03-10 | — | — | US | claimed |
| US-20090093451-A1 | IL-8 Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-09 | — | — | US | claimed |
| EP-3980409-A1 | PYRROLIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2022-04-13 | — | — | EP | disclosed |
| WO-2020247429-A1 | PYRROLIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2020-12-10 | — | — | WO | disclosed |
| WO-2013043826-A1 | TRICYCLIC COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | ABBVIE INC. (US) | 2013-03-28 | — | — | WO | disclosed |
| US-20110172238-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED | 2011-07-14 | — | — | US | disclosed |
| US-7268134-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7268134-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059937-A1 | IL-8 RECEPTOR ANTAGONISTS | CXCL8, CCR8, IL1RN | L3MBTL1 3467/4885POLB 4151/4885NPC1 1513/4885 |
| US-20110172238-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | BRI3BP, BLVRB, BRIX1 | L3MBTL1 154/4885POLB 1311/4885NPC1 1372/4885 |
| US-20090093451-A1 | IL-8 Receptor Antagonists | CXCL8, CCR8, IL1RN | L3MBTL1 3467/4885POLB 4151/4885NPC1 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.